CA2983022C - High throughput bh3 profiling: a rapid and scalable technology to bh3 profile on low numbers of cells - Google Patents

High throughput bh3 profiling: a rapid and scalable technology to bh3 profile on low numbers of cells Download PDF

Info

Publication number
CA2983022C
CA2983022C CA2983022A CA2983022A CA2983022C CA 2983022 C CA2983022 C CA 2983022C CA 2983022 A CA2983022 A CA 2983022A CA 2983022 A CA2983022 A CA 2983022A CA 2983022 C CA2983022 C CA 2983022C
Authority
CA
Canada
Prior art keywords
cells
buffer
profiling
domain peptide
kit
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2983022A
Other languages
English (en)
French (fr)
Other versions
CA2983022A1 (en
Inventor
Anthony Letai
Patrick BHOLA
Jeremy RYAN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dana Farber Cancer Institute Inc
Original Assignee
Dana Farber Cancer Institute Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dana Farber Cancer Institute Inc filed Critical Dana Farber Cancer Institute Inc
Publication of CA2983022A1 publication Critical patent/CA2983022A1/en
Application granted granted Critical
Publication of CA2983022C publication Critical patent/CA2983022C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5014—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing toxicity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5076—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving cell organelles, e.g. Golgi complex, endoplasmic reticulum
    • G01N33/5079—Mitochondria
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Food Science & Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
CA2983022A 2015-04-27 2016-04-27 High throughput bh3 profiling: a rapid and scalable technology to bh3 profile on low numbers of cells Active CA2983022C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562153475P 2015-04-27 2015-04-27
US62/153,475 2015-04-27
PCT/US2016/029495 WO2016176288A1 (en) 2015-04-27 2016-04-27 High throughput bh3 profiling: a rapid and scalable technology to bh3 profile on low numbers of cells

Publications (2)

Publication Number Publication Date
CA2983022A1 CA2983022A1 (en) 2016-11-03
CA2983022C true CA2983022C (en) 2023-03-07

Family

ID=57198812

Family Applications (2)

Application Number Title Priority Date Filing Date
CA2983024A Pending CA2983024A1 (en) 2015-04-27 2016-04-27 Compositions and methods for assessing toxicity using dynamic bh3 profiling
CA2983022A Active CA2983022C (en) 2015-04-27 2016-04-27 High throughput bh3 profiling: a rapid and scalable technology to bh3 profile on low numbers of cells

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CA2983024A Pending CA2983024A1 (en) 2015-04-27 2016-04-27 Compositions and methods for assessing toxicity using dynamic bh3 profiling

Country Status (6)

Country Link
US (4) US20180120297A1 (enExample)
EP (2) EP3289094B1 (enExample)
JP (3) JP6814745B2 (enExample)
AU (2) AU2016255749B2 (enExample)
CA (2) CA2983024A1 (enExample)
WO (2) WO2016176288A1 (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004022580A2 (en) 2002-09-09 2004-03-18 Dana-Farber Cancer Institute, Inc. Bh3 peptides and method of use thereof
US8221966B2 (en) 2006-03-31 2012-07-17 Dana Farber Cancer Institute Methods of determining cellular chemosensitivity
WO2014047342A1 (en) 2012-09-19 2014-03-27 Dana-Farber Cancer Institute, Inc. Dynamic bh3 profiling
JP6663852B2 (ja) 2013-09-19 2020-03-13 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド Ｂｈ３プロファイリングの方法
HK1247250A1 (zh) 2015-01-12 2018-09-21 Eutropics Pharmaceuticals, Inc. 用於指导癌症治疗的内容相关的诊断测试
WO2016149613A2 (en) 2015-03-18 2016-09-22 Massachusetts Institute Of Technology Selective mcl-1 binding peptides
JP6851978B2 (ja) 2015-04-20 2021-03-31 スミトモ ダイニッポン ファーマ オンコロジー， インコーポレイテッド ミトコンドリアプロファイリングによるアルボシジブ応答の予測
EP3289094B1 (en) 2015-04-27 2024-06-05 Dana-Farber Cancer Institute, Inc. Compositions and methods for assessing toxicity using dynamic bh3 profiling
JP6510075B2 (ja) 2015-05-18 2019-05-08 トレロ ファーマシューティカルズ， インコーポレイテッド バイオアベイラビリティが高いアルボシジブプロドラッグ
EP3331510A4 (en) 2015-08-03 2019-04-03 Tolero Pharmaceuticals, Inc. COMBINATION THERAPIES FOR THE TREATMENT OF CANCER
WO2018017922A2 (en) 2016-07-22 2018-01-25 Massachusetts Institute Of Technology Selective bfl-1 peptides
US11279694B2 (en) 2016-11-18 2022-03-22 Sumitomo Dainippon Pharma Oncology, Inc. Alvocidib prodrugs and their use as protein kinase inhibitors
CA3047557A1 (en) * 2016-12-19 2018-06-28 Tolero Pharmaceuticals, Inc. Profiling peptides and methods for sensitivity profiling
WO2019055579A1 (en) 2017-09-12 2019-03-21 Tolero Pharmaceuticals, Inc. TREATMENT REGIME FOR CANCERS THAT ARE INSENSITIVE TO BCL-2 INHIBITORS USING THE MCL-1 ALVOCIDIB INHIBITOR
EP3852783A1 (en) * 2018-09-17 2021-07-28 Massachusetts Institute of Technology Peptides selective for bcl-2 family proteins
US11034710B2 (en) 2018-12-04 2021-06-15 Sumitomo Dainippon Pharma Oncology, Inc. CDK9 inhibitors and polymorphs thereof for use as agents for treatment of cancer
WO2020176689A1 (en) * 2019-02-26 2020-09-03 Dana-Farber Cancer Institute, Inc. Live cell imaging dynamic bh3 profiling
US11793802B2 (en) 2019-03-20 2023-10-24 Sumitomo Pharma Oncology, Inc. Treatment of acute myeloid leukemia (AML) with venetoclax failure

Family Cites Families (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
ATE144793T1 (de) 1989-06-29 1996-11-15 Medarex Inc Bispezifische reagenzien für die aids-therapie
US5674980A (en) 1989-12-21 1997-10-07 Biogen Inc Fusion protein comprising tat-derived transport moiety
US5804604A (en) 1989-12-21 1998-09-08 Biogen, Inc. Tat-derived transport polypeptides and fusion proteins
DE69133566T2 (de) 1990-01-12 2007-12-06 Amgen Fremont Inc. Bildung von xenogenen Antikörpern
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
KR100272077B1 (ko) 1990-08-29 2000-11-15 젠팜인터내셔날,인코포레이티드 이종 항체를 생산할 수 있는 전이유전자를 가진 인간이외의 동물
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
WO1992020373A1 (en) 1991-05-14 1992-11-26 Repligen Corporation Heteroconjugate antibodies for treatment of hiv infection
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
WO1994002602A1 (en) 1992-07-24 1994-02-03 Cell Genesys, Inc. Generation of xenogeneic antibodies
ES2091684T3 (es) 1992-11-13 1996-11-01 Idec Pharma Corp Aplicacion terapeutica de anticuerpos quimericos y radiomarcados contra el antigeno de diferenciacion restringida de los linfocitos b humanos para el tratamiento del linfoma de las celulas b.
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
JP4312259B2 (ja) 1995-04-27 2009-08-12 アムジェン フレモント インク． 免疫したゼノマウス（ＸｅｎｏＭｏｕｓｅ）に由来するヒト抗体
EP0823941A4 (en) 1995-04-28 2001-09-19 Abgenix Inc HUMAN ANTIBODIES DERIVED FROM IMMUNIZED XENO MOUSES
AU705563B2 (en) 1995-07-28 1999-05-27 Marie Curie Cancer Care Transport proteins and their uses
JP3295431B2 (ja) * 1995-10-24 2002-06-24 サングスタット メディカル コーポレイション 抗アルファ−ガラクトシルスクリーニング技術
US5965703A (en) 1996-09-20 1999-10-12 Idun Pharmaceuticals Human bad polypeptides, encoding nucleic acids and methods of use
US5916771A (en) 1996-10-11 1999-06-29 Abgenix, Inc. Production of a multimeric protein by cell fusion method
WO1999014321A1 (en) 1997-09-17 1999-03-25 The Walter And Eliza Hall Institute Of Medical Research Novel therapeutic molecules
US20020029391A1 (en) 1998-04-15 2002-03-07 Claude Geoffrey Davis Epitope-driven human antibody production and gene expression profiling
EP1210098A1 (en) 1999-04-07 2002-06-05 Thomas Jefferson University Enhancement of peptide cellular uptake
WO2001012661A2 (en) 1999-08-16 2001-02-22 The Government Of The United States Of America, Asrepresented By The Secretary, Department Of Healthand Human Services, The National Institutes Of Health RECEPTOR-MEDIATED UPTAKE OF AN EXTRACELLULAR BCL-xL FUSION PROTEIN INHIBITS APOPTOSIS
WO2002020568A2 (en) 2000-09-06 2002-03-14 Abbott Laboratories Mutant peptides derived from bad and their use to identify substances which bind to a member of the bcl-2 family of proteins
US20020115613A1 (en) 2001-02-16 2002-08-22 Kumar M. Vijay Treatment of prostate cancer
WO2003040168A2 (en) * 2001-11-06 2003-05-15 Enanta Pharmaceuticals, Inc. Methods and compositions for identifying peptide aptamers capable of altering a cell phenotype
JP2005518393A (ja) * 2001-12-21 2005-06-23 アリアス リサーチ、インコーポレイテッド 個別化抗癌抗体
WO2004022580A2 (en) 2002-09-09 2004-03-18 Dana-Farber Cancer Institute, Inc. Bh3 peptides and method of use thereof
US20070032417A1 (en) 2002-12-24 2007-02-08 Walter And Eliza Hall Institute Of Medical Research Peptides and therapeutic uses thereof
WO2004083405A2 (en) 2003-03-19 2004-09-30 Alfa Wassermann, Inc. Separation and accumulation of subcellular components, and proteins derived therefrom
PT2332968T (pt) 2003-11-05 2016-08-17 Harvard College Péptidos alfa-helicoidais adequados para a activação ou inibição da morte celular
WO2006069186A2 (en) 2004-12-22 2006-06-29 The Ohio State Research Foundation Small molecule bcl-xl/bcl-2 binding inhibitors
JP2005130867A (ja) 2005-02-16 2005-05-26 Mitokor ミトコンドリア内カルシウムを使用するスクリーニングアッセイ
WO2006099667A1 (en) 2005-03-21 2006-09-28 The Walter And Eliza Hall Institute Of Medical Research Prophylactic and therapeutic agents and uses therefor
WO2007016254A2 (en) 2005-07-27 2007-02-08 The Board Of Trustees Of The University Of Arkansas Antineoplastic activities of ellipticine and its derivatives
US8221966B2 (en) * 2006-03-31 2012-07-17 Dana Farber Cancer Institute Methods of determining cellular chemosensitivity
US8518635B2 (en) 2006-06-12 2013-08-27 The J. David Gladstone Institutes Regulation of protein activity by reversible acetylation
KR100786759B1 (ko) 2006-07-07 2007-12-18 김현기 Ｈｃｃｒ-1을 포함하는 유방암 예후 마커 및 비만 유도조성물
US9360473B2 (en) 2006-08-16 2016-06-07 Eutropics Pharmaceuticals, Inc. Assay system to identify therapeutic agents
WO2008152405A2 (en) 2007-06-15 2008-12-18 The Queen's University Of Belfast Protein complexes comprising bh3 peptides and voltage dependent anion channel (vdac) peptides as well as uses thereof for the treatment of proliferative diseases
KR20100074177A (ko) 2007-09-10 2010-07-01 유니버시티 오브 매사추세츠 미토콘드리아-표적화된 항-종양 물질
CA2700925C (en) * 2007-09-26 2016-08-23 Dana Farber Cancer Institute Methods and compositions for modulating bcl-2 family polypeptides
JP2009240173A (ja) 2008-03-28 2009-10-22 Univ Of Tokushima パーキン蛋白の新規糖化因子
EA026732B1 (ru) 2009-06-11 2017-05-31 Минерва Байотекнолоджиз Корпорейшн Способы культивирования стволовых клеток и клеток-предшественников
WO2010147961A1 (en) 2009-06-15 2010-12-23 Precision Therapeutics, Inc. Methods and markers for predicting responses to chemotherapy
US20130122492A1 (en) * 2011-11-14 2013-05-16 Kellbenx Inc. Detection, isolation and analysis of rare cells in biological fluids
CN107315088A (zh) * 2012-05-10 2017-11-03 尤特罗皮克斯制药股份有限公司 对癌症的代理功能性诊断测试
US20150322479A1 (en) 2012-06-20 2015-11-12 Cytospan Technologies Corporation Apparatus and method for quantification of replicative lifespan and observation of senescene
WO2014047342A1 (en) 2012-09-19 2014-03-27 Dana-Farber Cancer Institute, Inc. Dynamic bh3 profiling
JP6327662B2 (ja) 2012-09-26 2018-05-23 学校法人藤田学園 細胞表面タンパクを抗原とする抗体を測定する方法
JP2016526892A (ja) 2013-07-18 2016-09-08 ユートロピクス ファーマシューティカルズ， インコーポレイテッド 示差的ｂｈ３ミトコンドリアプロファイリング
JP6663852B2 (ja) 2013-09-19 2020-03-13 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド Ｂｈ３プロファイリングの方法
EP3289094B1 (en) 2015-04-27 2024-06-05 Dana-Farber Cancer Institute, Inc. Compositions and methods for assessing toxicity using dynamic bh3 profiling
WO2017007858A1 (en) 2015-07-06 2017-01-12 Whitehead Institute For Biomedical Research Methods and compositions relating to proteasome inhibitor resistance
WO2020176689A1 (en) 2019-02-26 2020-09-03 Dana-Farber Cancer Institute, Inc. Live cell imaging dynamic bh3 profiling

Also Published As

Publication number Publication date
US10761086B2 (en) 2020-09-01
JP2018520638A (ja) 2018-08-02
AU2016253957B2 (en) 2020-10-22
AU2016253957A1 (en) 2017-10-19
JP6802185B2 (ja) 2020-12-16
US20210255167A1 (en) 2021-08-19
US20210041419A1 (en) 2021-02-11
WO2016176288A1 (en) 2016-11-03
US20180120297A1 (en) 2018-05-03
EP3288964A1 (en) 2018-03-07
CA2983024A1 (en) 2016-11-03
US11867688B2 (en) 2024-01-09
HK1252055A1 (en) 2019-05-10
EP3289094A1 (en) 2018-03-07
JP6814745B2 (ja) 2021-01-20
AU2016253957C1 (en) 2021-04-01
EP3288964B1 (en) 2024-02-21
CA2983022A1 (en) 2016-11-03
HK1252058A1 (en) 2019-05-10
JP2018514210A (ja) 2018-06-07
AU2016255749A1 (en) 2017-10-19
EP3288964A4 (en) 2018-10-31
EP3289094A4 (en) 2018-10-31
AU2016255749B2 (en) 2021-10-14
WO2016176299A1 (en) 2016-11-03
EP3289094B1 (en) 2024-06-05
JP2021036915A (ja) 2021-03-11
US20180128813A1 (en) 2018-05-10

Similar Documents

Publication Publication Date Title
US11867688B2 (en) High throughput BH3 profiling: a rapid and scalable technology to BH3 profile on low numbers of cells
EP1392342B1 (en) Global analysis of protein activities using proteome chips
Mendes et al. Optimization of the magnetic recovery of hits from one-bead–one-compound library screens
US20220163510A1 (en) Live cell imaging dynamic bh3 profiling
Head et al. Identification of small molecule-binding proteins in a native cellular environment by live-cell photoaffinity labeling
HK1252058B (en) High throughput bh3 profiling: a rapid and scalable technology to bh3 profile on low numbers of cells
HK1252055B (en) Compositions and methods for assessing toxicity using dynamic bh3 profiling
KR101444995B1 (ko) 세포질 단백질의 단백질-단백질 상호작용을 확인하는 방법
Loo et al. Repair of CFTR folding defects with correctors that function as pharmacological chaperones
WO2007058987A1 (en) Methods of identifying compounds that inhibit notch cleavage
Alsagaby Proteomics analysis of chronic lymphocytic leukaemia cells
WO2015007383A1 (en) Solid phase transfection of proteins and nucleic acids
KR20110051508A (ko) 단백질 상호작용 억제제 선별방법
AU2002316100A1 (en) Global analysis of protein activities using proteome chips

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20210122

EEER Examination request

Effective date: 20210122

EEER Examination request

Effective date: 20210122

EEER Examination request

Effective date: 20210122

EEER Examination request

Effective date: 20210122